RxDoctor Payments Data

Hanson Zhao, MD

Urology · Newport Beach, CANPI 1891297990

Payments from drug & device makers

$55,546in general payments, 2019–2025

Across 73 payments — averaging $760.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$53K
  • Intuitive Surgical$727
  • Ambu A/s$480
  • Medtronic$184
  • Endo Pharmaceuticals Inc.$165
  • Procept Biorobotics Corporation$153
  • plus $490 from 9 others

What the payments were for

  • Consulting fees$4801%
  • Speaking & faculty fees$3001%
  • Grants$50,00090%
  • Travel & lodging$2,0874%
  • Food & beverage$2,5885%
  • Education$910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,546 in reported general payments places this provider in the 85th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$405,614
Medicare patients
637
Services billed
4,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron45$35,913
GemtesaVibegron22$18,605
Tadalafil22$6,251
Trospium Chloride96$5,244
Tamsulosin Hcl359$4,544
Finasteride202$3,317
Methenamine Hippurate32$3,265
Estradiol26$2,660
Tolterodine Tartrate ErTolterodine Tartrate27$2,163
Dutasteride19$1,471
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$1,379
Cefdinir51$624
Ciprofloxacin Hcl119$619
Alfuzosin Hcl ErAlfuzosin Hcl33$502
Solifenacin Succinate13$322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$19$18,60522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,324 urology providers in California.

Other urology in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →